{
  "docId": "019de075-1597-7518-8ef8-7c76bda0fb5f",
  "docSlug": "a75249d5a456b06509b9b61a9aec1423",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 15,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "testimonial",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a split-screen layout: a personal story on the left and clinical/social burden data on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1597-7518-8ef8-7c76bda0fb5f/4",
  "deckHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f",
  "deckJsonHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f.json",
  "deckAnchorHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f#slide-4",
  "components": [
    {
      "bbox": {
        "h": 1,
        "w": 0.45,
        "x": 0,
        "y": 0
      },
      "kind": "image",
      "text": "Andrea",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb73332e-079a-45ac-952e-cc19c6bdc216",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.5,
        "y": 0.38
      },
      "kind": "metric",
      "text": "2.6 Years",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "444171e2-2244-4f7c-8b00-b87ea13dcae6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.5,
        "y": 0.78
      },
      "kind": "metric",
      "text": "35% of Patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f3631da-d31e-4053-a929-170542b7f519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.5,
        "y": 0.64
      },
      "kind": "metric",
      "text": "51% of Patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10bb52c-674d-4953-9812-a4772c8ed508",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.5,
        "y": 0.5
      },
      "kind": "metric",
      "text": "1/2 of Patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebbdf533-58cf-47f2-895a-fdbc9830fce2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.48,
        "x": 0.48,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "gMG is characterized by debilitating muscle weakness and fatigue. Despite taking an average of 2.3 current treatments, 61% of patients have poor well-being according to WHO-5 Index",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b5ef5a-74d6-4b59-a39c-081fbb953d98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "quote",
      "text": "VYVGART® Hytrulo has redefined my experience with gMG. I am grateful to have found a treatment built to my needs, empowering me to return to the activities I love.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ead2cc5-5112-435f-a735-4f455c446f48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.45,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Information from argenx market research",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccfd0371-055f-4ddd-924d-dead97163a5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.08
      },
      "kind": "title",
      "text": "GENERALIZED MYASTHENIA GRAVIS PATIENT EXPERIENCE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8860a267-541f-4fd1-b20c-91779951771c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Emotional Appeal",
      "slug": "emotional-appeal",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "7821108e-18c5-452e-81f9-5481a9ea0309",
      "evidence": "VYVGART® Hytrulo has redefined my experience with gMG. I am grateful to have found a treatment built to my needs, empowering me to return to the activities I love.",
      "confidence": 0.7
    },
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "7eeb7b0d-b256-4f50-829b-12d7c8416bd0",
      "evidence": "gMG is characterized by debilitating muscle weakness and fatigue. Despite taking an average of 2.3 current treatments, 61% of patients have poor well-being according to WHO-5 Index",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "a2efa267-8ecc-4b5d-9805-1293ed2ee6f7",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Key Messages",
      "beatSlug": null,
      "evidence": "Highlighting VYVGART's role in transforming gMG treatment",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 4,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "74bb5eb4-c259-4814-9d3c-a11f1e39a665",
      "evidence": "Generalized Myasthenia Gravis patient experience testimonial",
      "position": 1,
      "objective": "To present the patient's experience and perspective on gMG and VYVGART",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.7,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}